Status:
RECRUITING
Registry of Autoimmune Interstitial Lung Disease
Lead Sponsor:
EPIMAR registry
Collaborating Sponsors:
Sociedad Argentina de Reumatologia
Conditions:
Interstitial Lung Disease Due to Systemic Disease
Eligibility:
All Genders
18+ years
Brief Summary
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma. In recent years, with the advent of new diagnostic tools and ther...
Detailed Description
Autoimmune ILD (Ai-ILD) include ILD associated with connective tissue disease (CTD), ILD associated with antineutrophil cytoplasmic antibodies (ANCA-ILD) and interstitial pneumonia with autoimmune fin...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Diagnosis of ILD within the last 5 years according to the criteria of the multidisciplinary team composed of at least one pulmonologist and one rheumatologist, with or without respiratory symptoms.
- ILD defined by the presence of ground glass opacities and / or peribronchovascular or airspace consolidations and / or reticulations and / or traction bronchiectasis and / or honeycomb on high-resolution computed tomography (HRCT) within the last 12 months 17 .
- One of the following three criteria (see annex 1):
- Established or early stage CTD 18-30. IPAF according to ATS / ERS 2015 classification criteria 8 ANCA positivity by immunofluorescence confirmed by ELISA, with or without systemic vasculitis 31.
- Spirometry performed within the last 6 months before entering the registry.
- The participant must sign the informed consent voluntarily.
Exclusion
- Not being able to perform the clinical follow-up or the complementary studies required in the protocol.
- Not being able to be evaluated by a multidisciplinary team; at least a rheumatologist plus a pulmonologist.
- ILD associated with another non-autoimmune etiology according to the criteria of the multidisciplinary team (eg, occupational diseases, toxic)
Key Trial Info
Start Date :
April 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05365009
Start Date
April 10 2022
End Date
October 1 2027
Last Update
May 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Epimar Ii
Buenos Aires, Argentina